Strides Pharma Q2 Results: Stock jumps 13% on strong margin expansion; US guidance maintained

Strides Pharma’s Revenue increased by 4.6% on a year-on-year basis to ₹1,221 crore. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) increased by 25.4% from the year-ago period to ₹232 crore.

Leave a Reply

Your email address will not be published. Required fields are marked *